

# Cancer Incidence Data

## Sri Lanka 2008



National Cancer Control Programme,  
Ministry of Health & Indigenous Medicine

E-mail : [nccp@health.gov.lk](mailto:nccp@health.gov.lk)  
Web : [www://:nccp.health.gov.lk](http://www.nccp.health.gov.lk)

**Cancer Surveillance Team**

Dr. Eshani Fernando

Dr. Suraj Perera

Dr. Hemantha Amarasinghe

Dr. Chiranthika Vithana

Dr. Nirmala Jayanthi

Dr. Kamal Seneviratna

Dr. Asanga Hemaratna

Dr. Pushpika Samarakoon

Dr. Ruwanmalie Liyanagama

Dr. L..D. Ratnasiri

Sr. Chamila Peiris

ISBN: 978-955-0505-66-1

National Cancer Control Programme-2014

10<sup>th</sup> Publication

Printed by: MG Printers & Publishers

## Contributors

### Data collection

Dr. K.G. Nirrmala Jayanthi  
Dr. Asanga Hemaratna  
Dr. Pushpika Samarakoon  
Dr. K.D. Ratnasiri  
Dr. Methsala Gunawardana  
Dr. A.W. Kaushika Dilrukshi  
Dr. B.G. Anushka Ratnamali  
Dr. W.A.I.W Gunathilake

Dr. P.R.T.D. Peramuna  
Dr. W.D.D.N. Seneviratne  
Dr. U.D.T.M. Weerasingha  
Dr. Gayani Isanka  
Dr. S.A. Himala Dilani Wijekoon  
Dr. R.W. Keshika  
Dr. .D.M.H.N. Disanayake

### Data coding

Dr. Nirrmala Jayanthi  
Dr. Asanga Hemaratna  
Dr. Pushpika Samarakoon

Dr. Ruwanmalie Liyanagama  
Dr. Kamani Ruhunage  
Sr. Chamila Peiris

### Verification

Dr. Nirrmala Jayanthi and Dr. Eshani Fernando

### Data entry

Ms. Nimesha Prasadi  
Ms. Prabashi Gayanthika

### Statistical analysis and editing

Dr. Eshani Fernando

Special Acknowledgement Dr. W. N. D. Paranagama (Former Director/NCCP)  
Special thanks to Mr Dilip Hensman of the WHO for the GIS mapping.

### Support staff

Mr. M.W. Saman Kumara Mahalekam  
Ms. Thushari Dhammika  
Mr. U.K. Sumanasiri  
Mr. Siripala Perera

## **Message from Director General of Health Services**



It is a great pleasure to issue a message to the 10<sup>th</sup> edition of 'Cancer Incidence Data: Sri Lanka' published by the National Cancer Control Programme of the Ministry of Health.

This publication gives a detailed description of cancer incidence data of year 2008 reported from hospitals where treatment for cancer is provided (Cancer treatment units, OMF units) & from pathology laboratories where diagnosis is confirmed. It is observed that over the years coverage of cancer incidence is improving. In addition to coverage, quality of data and timeliness of data need to be further improved. In order to achieve that, active participation of health care staff is highly required.

I wish policy planners, health care service providers, clinicians and researchers will utilize these data. I appreciate the hard work of Director and staff of the National Cancer Control Programme and continued support of World Health Organization for this activity.

**Dr. Palitha Mahipala**

Director General of Health Services



## **Message from Deputy Director General of Medical Services**



I am pleased to issue a message to the 10<sup>th</sup> edition of 'Cancer Incidence Data: Sri Lanka' published by the National Cancer Control Programme of Ministry of Health.

The information related to cancer incidence is important for planning, implementation, monitoring & evaluation of programmes related to prevention & control of cancers. It is observed that in addition to cancer incidence data reported to cancer treatment units & OMF units, newly diagnosed cancers at the pathology laboratories are also incorporated.

I would like to thank the Director and the staff of the National Cancer Control Programme and other stakeholders for generating this publication, which is a useful tool to understand the current status of cancer incidence.

**Dr. Lakshmi Somathunga**

Deputy Director General of Medical Services

## Forward



Publication of cancer incidence data is one of the main responsibilities of the National Cancer Control Programme. The National Cancer Control Programme has come a long way in publishing cancer incidence data of Sri Lanka since its first publication in 1985. From a few data capturing points in 1985, data capturing points has increased to 40 in 2009 making the coverage closer to the ideal.

The cancer incidence data are of national importance for development of cancer control strategies, resource allocation for cancer care and for generating hypothesis for future research on cancer. I sincerely hope that the data published in this series would be used by researchers in the field.

I wish to place on record my sincere appreciation to the WHO for the continued support given for cancer surveillance in Sri Lanka and to Mr. Dilip Hensman for providing the GIS maps. I wish to thank the cancer surveillance team for their dedication, hard work and commitment towards this nationally important task.

Dr. Eshani Fernando,  
Acting Director, National Cancer Control Programme

## Table of Contents

	Page No.
Cancer surveillance team	ii
Contributors	iii
Message from the Director General of Health Services	v
Message from the Deputy Director General of Health Services I	vii
Forward	ix
List of tables	xi
List of figures	xii
Executive Summary	1
Introduction	2
Methodology	2
Data tables and Graphs	4
List of references	62
Appendix I- Statistical Terminology	63

## List of Tables

Table No.	Description	Page No.
01	General Population: Sex Distribution	4
02	Denominators used for calculation of the Cancer Registry	4
03	Statistics on doctors, hospitals and hospital beds	5
04	Cancer Incidence in Sri Lanka -2008	5
05	Overall Cancer Incidence, 2008 by age and sex	6
06	Leading cancer sites- 2008	7
07	Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites- 2008	8
08	Cancer cases by age group-Male 2008	15
09	Cancer cases by age group-Female 2008	17
10	Cancer cases by ethnicity, sex and sub-site, 2008	19
11	Cancer incidence by site and histological type 2008	21
12	Lip, oral cavity and pharynx	27
13	Lip and anterior part of oral cavity	29
14	Posterior part of oral cavity and pharynx	30
15	Trachea, bronchus and lungs	31
16	Larynx	32
17	Oesophagus	33
18	Stomach	34
19	Colon and rectum	35
20	Colon	36
21	Rectum, anal canal and anus	37
22	Breast	38
23	Cervix uteri	39
24	Ovary	40
25	Skin	41
26	Brain	42
27	Thyroid gland	43
28	Urinary Bladder	44
29	Hematopoietic and reticuloendothelial system	45

<b>Table No.</b>	<b>Description</b>	<b>Page No.</b>
30	Prostate gland	46
31	Site and family history of cancer	48
32	Site of cancer and bilateral organ involvement	48
33	Basis of diagnosis of cancer patients 2008	49
34	Cancer Treatment 2008	50
35	Cancer Incidence by Geographical area 2008	52

### List of Figures

<b>Figure No.</b>	<b>Description</b>	<b>Page No.</b>
01	General population of Sri Lanka by 5-year age groups- 2000 & 2008	4
02	Cancer Incidence Rates 2008	5
03	Age Specific Cancer Incidence Rates 2008	6
04	Leading cancer sites 2008	9
05A	Leading cancers by age group: 0-14 years	10
05B	Leading cancers by age group: 15-34 years	11
05C	Leading cancers by age group: 35-49 years	12
05D	Leading cancers by age group: 50-64 years	13
05E	Leading cancers by age group: 65 years and above	14
06	Age specific rates-Lip, oral cavity and pharynx	28
07	Age specific rates-Trachea, bronchus and lungs	31
08	Age specific rates- Larynx	32
09	Age specific rates- Oesophagus	33
10	Age specific rates- Stomach	34
11	Age specific rates- Colon and rectum	35
12	Age specific rates- Colon	36
13	Age specific rates- Rectum, anal canal and anus	37
14	Age specific rates- Breast	38
15	Age specific rates- Cervix uteri	39
16	Age specific rates- Ovary	40
17	Age specific rates- Skin	41
18	Age specific rates- Brain	42
19	Age specific rates- Thyroid gland	43
20	Age specific rates- Urinary bladder	44
21	Age specific rates- Hematopoietic and reticuloendothelial system	45
22	Age specific rates- Prostate gland	46
23	Stage at diagnosis- Cervical cancer	47
24	Stage at diagnosis- Breast cancer	47
25	Stage at diagnosis- oral cancer	47
26	Basis of diagnosis	49
27	Basis of diagnosis by major categories	49
28	Percentage of patients who received different types of treatment	51
29	Cancer Incidence by Districts- 2008	53
30	Male Cancer Incidence by Districts- 2008	56
31	Female Cancer Incidence by Districts- 2008	59

## Executive summary

This 2008 publication of cancer incidence data of Sri Lanka is the 10th volume in the series of publications. The number of data sources have increased from 10 in 2007 (6 cancer treatment centres and 4 oral and maxillofacial surgery units) to 40 sources (7 cancer treatment centres, 17 maxillofacial surgery units and 16 pathology laboratories) in 2008 making the process of checking for duplicate entries a very tedious process. In 2008, a total of 16,511 new cancer cases were diagnosed in Sri Lanka. This a considerable increase from the 2007 figure which was 13, 635. The percentage increase of the number of cases diagnosed from 2007 to 2008 is 20%. When the age standardized rates of cancer incidence of these years were compared, an increase of 20.6% was noted. The main contributor for this increase could be the addition of 16 new data sources. Over 2200 new cases were reported only from the pathology laboratories. If the cases which were reported only from pathology laboratories were not considered, the percentage increase in the number of cases would be 4.9%. For calculation of trends in incidence, the value of 4.9% would be more realistic.

The overall crude cancer incidence rate (CR) was 81.6 per 100,000 population and the age standardized rate (ASR) was 86.4 per 100, 000 population. The same 10 cancers remained in the top 10 positions in 2008 as well.

The leading cancer in Sri Lanka was breast cancer followed by cancers of the 'lip, oral cavity and the pharynx'. The CR and ASR of breast cancer were 11.3 and 11.6 per 100,000 population respectively. The percentage increase of rates (15% -CR and 17% -ASR) from 2007 to 2008 could also be partly attributed to the increased number of data sources. The CR and the ASR of breast cancer among females were 21.8.

Cancers of the 'lip, oral cavity and the pharynx' remained the leading cancer among males in 2008 as well with a CR of 16.2 and an ASR of 18.1 per 100,000 population. The five leading cancers among males were, 'lip, oral cavity and the pharynx', 'trachea, bronchus and lung', oesophagus, 'colon and rectum', and lymphoma.

The five leading cancer sites among females were breast, cervix uteri, thyroid gland, oesophagus and the 'colon and rectum'.

The life time risk of developing any type of cancer (calculated for 0-74 years) in the population was one in every 10 persons for both males and females.

Treatment received by cancer patients diagnosed in 2008 was as follows. Out of all patients, 35% had received surgery, 43% had received radiotherapy, 46% chemotherapy and 10% hormone therapy whereas 3% had received only symptomatic treatment.

The percentage of microscopically confirmed cases was 94.6% out of which 87.1% were diagnosed by histology of the primary site.

## Introduction

The National Cancer Control Programme of Sri Lanka was established in 1980. Publication of the cancer incidence data commenced in 1990 presenting the data of 1985 collected from the cancer treatment centres. This annual publication continued for three years up to 1987. Thereafter the publications were done every 5 years due to logistic issues. Considering the importance of timely dissemination of information, annual publication of cancer incidence data was recommenced from 2006. Until 2006, cancer incidence data were obtained only from the cancer treatment centres in the country. From 2006, data from the oral and maxillofacial surgery units were also incorporated for analysis. In addition to these data sources, data from pathology laboratories in government hospitals were also included in the analysis from this year making the number of data capturing points to 40. This publication presents cancer incidence data of 2008. Data on mortality of cancer patients are not reported in this publication as cause specific mortality data are not available for 2008 in the Registrar General's Department until the time of publication.

## Methodology

Cancer incidence data of 2008 represents data collected from the 7 (seven) cancer treatment centres which were operational in 2008, 17 (seventeen) Oral & Maxillofacial Surgery Units and 16 (sixteen) Pathology laboratories of government hospitals. The data sources are given below.

### Cancer Treatment Centres:

National Cancer Institute, Maharagama  
Teaching Hospitals, Kandy, Karapitiya, Jaffna and Anuradapura  
Provincial General Hospitals Badulla and Kurunegala

### Oral & Maxillo- Facial Surgery Units in:

Dental Institute, Colombo  
Teaching Hospitals, Anuradhapura, Colombo South, Kandy, Karapitiya and Ragama  
Provincial General Hospital, Badulla  
District General Hospitals, Chillaw, Gampaha, Kalutara, Matale, Matara, Polonnaruwa and Kegalle  
Base Hospital, Avissawella, Kuliypitiya and Panadura

### Pathology Laboratories in:

National Hospital Sri Lanka  
De Soysa Hospital for Women  
Castle Street Hospital for Women  
Lady Ridgeway Hospital  
Medical Research Institute  
Faculty of Medicine, Karapitiya  
National Cancer Institute, Maharagama  
National Eye Hospital  
Teaching Hospitals, Colombo North, Kandy and Welisara (Chest)  
District General Hospitals, Gampaha, Kalutara and Negombo  
Base Hospitals, Wathupitiwela and Balapitiya

extract relevant data for the cancer registry. Initially, data retrieval was done under close supervision by registry staff and later, a random sample was checked to improve reliability of data. Data quality checks were made during coding and at the basic analysis level. The clinic record numbers of data sheets with errors were noted and the relevant patient files were re-examined and necessary corrections were done to the data sheets. Data of the Jaffna cancer treatment centre were collected by the centre and sent directly to the registry.

Data from the Oral & Maxillofacial Surgery Units and the Pathology laboratories were collected passively using data collection formats supplied by the NCCP to these institutions.

The date of first histological or cytological confirmation or the date of confirmation by clinical investigation was taken as the date of incidence. In instances this information was not available; date of admission to the hospital due to the malignancy was taken as the incidence date.

International Classification of Disease for Oncology (ICDO-3) was used for topographical and morphological coding. This cleaned data was then fed to the computer using CanReg5 package by two data entry operators who had been trained by the registry staff. Due to the increased number of data capturing points in 2008, especially the pathology laboratories, duplicate searching was a laborious process. In addition to the duplicate search facility of CanReg5, excel sheets were also utilised to identify duplicate entries which were not identified by the Canreg5 software due to minor changes in spelling of names, addresses etc. All multiple entries due to patients being registered in more than one treatment centre were identified and removed from the database using the duplicate searching mechanisms in the software by matching basic information of the patient, demographic variables, topography and morphology.

Cases under behaviour code '3' (Malignant primary site) only was included in the analysis by excluding behaviour codes '1' (uncertain whether benign or malignant borderline malignancy) and '2' (carcinoma in situ) to be on par with international standards. Patients in whom cancer had been ruled out and suspected cases whose diagnosis had not been confirmed yet were omitted from the registry.




Figure 01: General population in Sri Lanka by 5-year age groups

Table 01: General population: Sex Distribution

Population ('000)	Year							
	2001	2002	2003	2004	2005	2006	2007	2008
Male	9,359	9,350	9,475	9,678	9,782	9,889	9,956	10,060
Female	9,438	9,571	9,698	9,757	9,862	9,969	10,083	10,186
Sex Ratio <sup>1</sup>	99.2	97.7	97.7	99.2	99.2	99.2	98.7	98.8

<sup>1</sup> Number of males per 100 females

Source: Department of Census and Statistics

Table 02: Denominators used for calculations in the Cancer Registry

Population ('000)	Year
	2008
Male	10,060
Female	10,186
Total	20,246

Source: Department of Census and Statistics



**Table 03: Statistics on doctors, hospitals and hospital beds**  
(Government Institutions)


	Year						
	2001	2002	2003	2005	2006	2007	2008
Doctors (MOO+DSS)	9,135	10,157	NA	11,152	11,460	12,337	13,337
Population per doctor	2,058	1,863	NA	1,764	1,733	1,625	1518
Hospitals	569	576	607	608	614	615	647
Beds	57,946	59,144	59,262	61,594	67,024	68,694	67,942
Beds per 1000 population	3.1	3.1	3.1	3.2	3.4	3.4	3.4

NA- Not Available

Source: Medical Statistics Unit, Ministry of Health

**Table 04: Cancer Incidence in Sri Lanka- 2008**


Sex	Number	%	CR	ASR
Male	7695	46.6	76.5	85.5
Female	8816	53.4	86.6	88.0
Total	16511	100.0	81.6	86.4



**Figure 02: Cancer Incidence Rates 2008**

**Table 05: Overall Cancer Incidence, 2008 by age and sex**

Age group	Male			Female			Total		
	Cases	Population	Incidence	Cases	Population	Incidence	Cases	Population	Incidence
Not Known	22			22			44		
0-4	96	876	11.0	97	846	11.5	193	1,722	11.2
5-9	64	901	7.1	52	873	6.0	116	1,774	6.5
10-14	49	928	5.3	51	896	5.7	100	1,824	5.5
15-19	83	997	8.3	97	973	10.0	180	1,970	9.1
20-24	100	953	10.5	126	950	13.3	226	1,903	11.9
25-29	101	789	12.8	180	814	22.1	281	1,603	17.5
30-34	114	760	15.0	300	783	38.3	414	1,543	26.8
35-39	171	744	23.0	462	761	60.7	633	1,505	42.1
40-44	329	697	47.2	688	703	97.9	1017	1,400	72.6
45-49	541	608	89.0	972	624	155.8	1513	1,232	122.8
50-54	900	540	166.7	1125	557	202.0	2025	1,097	184.6
55-59	1092	387	282.2	1218	416	292.8	2310	803	287.7
60-64	1205	288	418.4	1157	305	379.3	2362	593	398.3
65-69	1015	224	453.1	898	260	345.4	1913	484	395.2
70-74	864	170	508.2	713	193	369.4	1577	363	434.4
75+	949	198	479.3	658	232	283.6	1607	430	373.7
<b>Total</b>	<b>7695</b>	<b>10,060</b>	<b>76.5</b>	<b>8816</b>	<b>10,186</b>	<b>86.6</b>	<b>16511</b>	<b>20,246</b>	<b>81.6</b>



**Figure 03: Age Specific Cancer Incidence Rates- 2008**

**Table 06: Leading cancer sites-2008**

Rank	Male				Female				Total			
	Site	No.	CR	ASR	Site	No.	CR	ASR	Site	No.	CR	ASR
1	Lip, oral cavity and pharynx	1630	16.2	18.1	Breast	2220	21.8	21.8	Breast	2283	11.3	11.6
2	Trachea, bronchus and lungs	814	8.1	9.3	Cervix uteri	858	8.4	8.6	Lip, oral cavity and pharynx	2107	10.4	11.2
3	Oesophagus	664	6.6	7.5	Thyroid gland	815	8.0	7.4	Cervix uteri	858	8.4	8.6
4	Colon and rectum	477	4.7	5.3	Ovary	637	6.3	6.2	Oesophagus	1281	6.3	7.0
5	Lymphoma	434	4.3	4.6	Oesophagus	617	6.1	6.4	Ovary	637	6.3	6.2
6	Unknown primary site	423	4.2	4.7	Colon and rectum	508	5.0	5.2	Thyroid gland	1020	5.0	4.8
7	Prostate gland	396	3.9	4.6	Lip, oral cavity and pharynx	477	4.7	4.8	Trachea, bronchus and lungs	1009	5.0	5.5
8	Larynx	393	3.9	4.4	Uterus	397	3.9	4.1	Colon and rectum	985	4.9	5.2
9	Leukaemia	344	3.4	3.7	Unknown primary site	296	2.9	3.0	Prostate	396	3.9	4.6
10	Stomach	239	2.4	2.7	Lymphoma	288	2.8	2.8	Lymphoma	722	3.6	3.7
	<b>All sites</b>	<b>7695</b>	<b>76.5</b>	<b>85.5</b>	<b>All sites</b>	<b>8816</b>	<b>86.6</b>	<b>88.0</b>	<b>All sites</b>	<b>16511</b>	<b>81.6</b>	<b>86.4</b>

CR: Crude rate per 100,000 population

ASR: Age standardized rate per 100,000 world population

The cumulative incidence rate given in Table 07 is a summary measure of the age specific incidence rates from 0-74 years. It is the summation of values of all the age specific incidence rates multiplied by 5 (as incidence rates were calculated for 5 year age groups) expressed per 100 persons in the population.



The life time risk of developing the leading cancers is also given in Table 07. The life time risk is given as a percentage, the risk of developing a particular cancer per 100 persons in the population as well as risk of developing a particular cancer given as number of persons per new case developed. One in every 10 males and females will develop cancer during their lifetime (0-74 years).

**Table 07: Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years)  
of leading cancer sites- 2008**



ICD O Code	Site	Male		Female		Total	
		Cumulative Rate	Lifetime Risk % <sup>1</sup> (n) <sup>2</sup>	Cumulative Rate	Lifetime Risk % (n)	Cumulative Rate	Lifetime Risk % (n)
C00-C06, C09-C14	Lip, oral cavity and pharynx	2.228	2.203 (45)	0.581	0.580 (172)	1.368	1.359 (74)
C15	Oesophagus	0.951	0.946 (106)	0.827	0.824 (121)	0.887	0.883 (113)
C16	Stomach	0.331	0.330 (303)	0.109	0.109 (917)	0.215	0.215 (465)
C18-C20	Colon and rectum	0.635	0.632 (158)	0.644	0.642 (156)	0.639	0.637 (157)
C32	Larynx	0.585	0.583 (172)	0.060	0.060 (1667)	0.310	0.309 (324)
C33-C34	Trachea, bronchus and lungs	1.229	1.221 (82)	0.261	0.261 (383)	0.721	0.719 (139)
C50	Breast	0.080	0.080 (1250)	2.456	2.426 (41)	1.308	1.299 (77)
C53	Cervix uteri	-	-	1.021	1.016 (98)	-	-
C54-C55	Uterus	-	-	0.521	0.519 (193)	-	-
C56	Ovary	-	-	0.702	0.700 (143)	-	-
C61	Prostate gland	0.584	0.582 (172)	-	-	-	-
C73	Thyroid gland	0.211	0.211 (474)	0.709	0.707 (141)	0.466	0.465 (215)
C80	Unknown primary site	0.590	0.588 (170)	0.390	0.389 (257)	0.486	0.484 (207)
	Lymphoma	0.483	0.482 (207)	0.322	0.322 (311)	0.400	0.400 (250)
	Leukaemia	0.330	0.329 (304)	0.236	0.235 (426)	0.280	0.280 (357)
	<b>All sites</b>	<b>10.289</b>	<b>9.777 (10)</b>	<b>10.050</b>	<b>9.562 (10)</b>	<b>10.132</b>	<b>9.636 (10)</b>

1- %- Life time risk as a percentage (per 100 persons)



2- (n)- Number of population per one new case detected





**Figure 04: Leading Cancer Sites 2008**



**Figure 05A: Leading cancers by age group: 0-14 years**





**Figure 05B: Leading cancers by age group: 15-34 years**





**Figure 05C: Leading cancers by age group: 35-49 years**





**Figure 05D: Leading cancers by age group: 50-64 years**



**Figure 05E: Leading cancers by age group: 65 years & above**

Table 08: Cancer cases by age group-Male 2008

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C00 Lip	0	0	0	0	0	0	0	0	0	2	2	5	6	15	4	3	6
C01 Base of tongue	0	0	0	0	0	0	0	0	1	1	11	15	19	12	14	8	5
C02 Other and unspecified parts of tongue	2	0	0	0	0	0	1	1	9	12	34	55	48	56	32	30	32
C03 Gum	0	0	0	0	0	0	1	0	3	3	8	11	15	11	17	13	15
C04 Floor of mouth	0	0	0	0	0	0	0	0	2	2	12	16	20	15	8	6	8
C05 Palate	0	0	0	0	0	0	1	2	0	4	15	24	16	17	7	10	15
C06 Other and unspecified parts of mouth	0	0	0	0	0	0	1	1	8	15	33	54	63	71	56	65	76
C07 Parotid gland	1	0	0	0	1	0	0	1	2	5	2	0	2	3	6	2	6
C08 Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	2	1	2	3	2	2	1	2
C09 Tonsil	0	0	2	0	0	0	0	0	3	4	16	18	20	18	12	9	9
C10 Oropharynx	0	0	0	0	0	0	0	0	2	1	6	10	12	11	7	7	6
C11 Nasopharynx	0	0	0	0	3	2	0	0	0	3	4	3	4	3	3	1	2
C12 Pyriform sinus	0	0	0	0	0	0	0	0	0	3	12	26	26	20	36	20	24
C13 Hypopharynx	0	0	0	0	1	0	0	1	0	1	3	3	6	5	7	3	3
C14 Other and ill-defined sites in lip, oral cavity and pharynx	0	0	0	0	0	0	0	1	0	2	4	3	13	6	8	7	4
C15 Oesophagus	2	0	0	0	0	1	0	2	4	19	40	91	115	123	91	85	91
C16 Stomach	1	0	0	0	1	0	1	1	4	7	19	36	44	38	38	22	27
C17 Small intestine	0	0	0	0	1	0	0	0	0	1	1	2	5	4	5	5	1
C18 Colon	1	0	0	0	0	1	2	6	4	19	22	29	20	35	24	24	23
C19 Rectosigmoid junction	0	0	0	0	0	0	0	0	0	2	0	2	6	2	3	4	3
C20 Rectum	0	0	0	0	0	3	2	3	6	10	19	25	20	60	28	26	43
C21 Anus and anal canal	0	0	0	0	0	0	0	1	1	5	4	1	4	7	4	1	3
C22 Liver and intrahepatic bile ducts	1	4	2	1	0	0	0	1	1	0	1	13	19	26	29	18	13
C23 Gallbladder	0	0	0	0	0	0	0	1	0	0	0	1	2	2	0	1	2
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	0	0	1	2	0	2	5	8	7	1	4	3
C25 Pancreas	0	0	0	0	0	0	1	2	5	1	5	10	15	2	8	4	5
C26 Other and ill-defined digestive organs	0	0	0	0	0	0	0	0	0	0	0	1	1	4	1	1	0
C30 Nasal cavity and middle ear	0	0	0	0	0	0	0	0	0	1	1	0	2	2	2	4	2
C31 Accessory sinuses	0	0	0	0	0	0	0	1	2	2	5	1	4	5	6	6	3
C32 Larynx	1	0	0	0	0	0	1	1	0	18	21	60	72	65	61	53	40
C33 Trachea	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C34 Bronchus and lung	1	0	0	0	0	1	0	4	6	27	50	101	142	147	141	106	87
C37 Thymus	0	0	1	0	0	2	0	0	0	0	0	1	1	2	1	1	0
C38 Heart, mediastinum and pleura	0	0	2	1	6	1	3	1	2	2	0	0	4	1	2	5	0
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40 Bones, joints and articular cartilage of limbs	0	1	3	3	13	12	3	0	2	0	1	0	1	0	2	0	0
C41 Bones, joints and articular cartilage of other and unspecified sites	0	2	0	1	3	1	6	0	0	2	2	3	0	3	2	1	0

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C42 Hematopoietic and reticuloendothelial systems	0	47	25	29	15	18	24	16	16	32	27	48	48	52	60	51	56
C44 Skin	3	0	0	1	1	3	2	3	1	13	11	30	26	24	18	23	21
C47 Peripheral nerves and autonomic nervous system	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	1	0
C48 Retroperitoneum and peritoneum	0	2	0	0	0	0	0	1	2	1	1	1	2	1	2	1	2
C49 Connective, subcutaneous and other soft tissues	1	1	2	0	6	7	1	5	6	12	6	7	5	7	5	2	2
C50 Breast	1	0	0	0	0	0	0	0	5	6	4	6	9	6	12	5	9
C60 Penis	0	0	0	0	0	0	0	0	4	3	6	7	16	15	2	11	10
C61 Prostate gland	3	0	0	0	0	0	0	0	0	0	3	12	35	65	70	87	121
C62 Testis	0	1	0	0	6	6	1	1	7	3	3	1	1	2	0	3	3
C63 Other and unspecified male genital organs	0	0	0	0	0	0	1	0	1	0	0	1	1	0	0	0	0
C64 Kidney	0	12	3	0	0	1	1	2	4	4	8	12	14	18	11	7	10
C65 Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0
C66 Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
C67 Bladder	0	0	0	0	0	1	0	0	1	5	10	17	34	39	35	41	52
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1
C69 Eye and adnexa	0	14	2	0	1	0	1	1	1	1	1	1	3	1	2	0	7
C70 Meninges	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
C71 Brain	1	2	9	3	4	10	6	14	11	6	11	11	13	20	10	4	3
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	0	0	1	1	0	0	0	2	0	1	0	0	1	0	0
C73 Thyroid gland	2	0	0	0	3	6	21	19	19	17	21	27	16	25	13	7	9
C74 Adrenal gland	0	2	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75 Other endocrine glands and related structures	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
C76 Other and ill-defined sites	0	4	0	0	0	0	1	0	0	2	5	6	3	4	1	2	5
C77 Lymph nodes	0	3	10	10	17	18	16	13	18	23	31	32	39	48	33	22	33
C80 Unknown primary site	0	0	0	0	0	3	2	7	6	22	35	52	69	72	69	40	46
<b>Total</b>	<b>22</b>	<b>96</b>	<b>64</b>	<b>49</b>	<b>83</b>	<b>100</b>	<b>101</b>	<b>114</b>	<b>171</b>	<b>329</b>	<b>541</b>	<b>900</b>	<b>1092</b>	<b>1205</b>	<b>1015</b>	<b>864</b>	<b>949</b>

Table 09: Cancer cases by age group-Female 2008

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C00 Lip	0	0	0	0	0	0	0	0	0	3	1	1	1	2	4	2	5
C01 Base of tongue	0	0	0	0	0	0	0	0	0	1	1	3	2	3	1	4	1
C02 Other and unspecified parts of tongue	2	0	0	0	0	1	1	1	1	3	3	9	12	13	4	5	11
C03 Gum	0	0	0	0	0	0	0	1	0	1	6	5	5	5	11	4	5
C04 Floor of mouth	0	0	0	0	0	0	0	0	0	1	0	2	2	0	1	2	2
C05 Palate	0	0	0	0	1	0	0	0	0	1	1	4	4	5	6	4	6
C06 Other and unspecified parts of mouth	2	0	0	1	0	0	0	0	5	6	10	19	26	21	29	21	38
C07 Parotid gland	0	0	0	1	3	3	2	0	5	6	2	4	1	5	2	1	2
C08 Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	1	1	3	2	0	1	3	1
C09 Tonsil	0	0	0	0	1	0	0	1	0	3	0	4	1	2	2	3	1
C10 Oropharynx	0	0	0	0	0	0	0	1	0	0	1	1	0	1	2	1	0
C11 Nasopharynx	0	0	0	0	2	1	2	0	0	0	0	3	3	2	2	1	0
C12 Pyriform sinus	0	0	0	0	0	0	0	0	2	2	2	3	1	3	5	4	2
C13 Hypopharynx	0	0	0	0	0	0	1	0	0	2	3	5	10	1	3	5	2
C14 Other and ill-defined sites in lip, oral cavity and pharynx	0	0	0	0	1	0	0	0	0	1	4	0	3	2	2	2	1
C15 Oesophagus	0	0	0	0	0	1	0	1	7	24	32	67	78	117	108	87	95
C16 Stomach	0	0	0	0	0	1	0	0	1	0	10	7	11	13	16	11	5
C17 Small intestine	0	0	0	0	0	0	0	0	1	1	3	2	2	4	0	0	1
C18 Colon	0	0	0	1	0	1	2	6	8	18	33	32	36	39	17	28	17
C19 Rectosigmoid junction	0	0	0	1	0	0	0	0	1	3	2	1	4	2	4	1	1
C20 Rectum	1	0	0	0	0	3	3	2	8	10	20	26	38	55	30	30	24
C21 Anus and anal canal	0	0	0	0	0	0	0	0	0	1	0	3	3	5	0	3	7
C22 Liver and intrahepatic bile ducts	2	9	0	0	0	0	0	0	0	1	0	8	0	8	7	6	0
C23 Gallbladder	0	0	0	0	0	0	0	1	0	0	3	6	2	4	1	5	7
C24 Other and unspecified parts of biliary tract	0	0	0	0	1	0	0	0	2	1	6	2	2	4	4	3	6
C25 Pancreas	0	0	0	0	1	0	0	0	1	1	5	9	6	4	4	2	3
C26 Other and ill-defined digestive organs	0	0	0	0	0	0	0	0	0	1	1	0	0	3	2	0	1
C30 Nasal cavity and middle ear	0	0	0	0	0	0	0	0	0	1	2	1	0	1	1	1	0
C31 Accessory sinuses	0	0	0	0	0	0	1	0	0	1	0	3	0	1	2	1	1
C32 Larynx	0	0	0	0	0	0	0	1	1	1	1	11	10	5	2	9	7
C33 Trachea	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0
C34 Bronchus and lung	2	0	0	0	1	0	4	1	4	8	8	31	26	30	24	33	21
C37 Thymus	0	0	0	0	0	0	0	1	1	1	2	1	1	2	0	1	0
C38 Heart, mediastinum and pleura	0	2	0	2	0	0	1	0	0	0	0	1	1	1	0	0	0
C40 Bones, joints and articular cartilage of limbs	0	1	2	4	4	3	3	2	0	1	1	0	0	1	1	1	0
C41 Bones, joints and articular cartilage of other and unspecified sites	0	1	1	5	4	1	1	0	0	0	1	2	1	0	3	1	0
C42 Hematopoietic and reticuloendothelial systems	2	44	22	12	22	12	15	19	15	29	30	40	52	59	42	40	47
C44 Skin	1	0	1	1	3	0	5	4	5	9	15	13	17	15	19	18	27

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C47 Peripheral nerves and autonomic nervous system	0	3	0	0	0	0	1	0	0	0	0	1	0	2	0	0	0
C48 Retroperitoneum and peritoneum	0	2	0	0	0	0	1	1	2	2	1	3	3	1	1	2	0
C49 Connective, subcutaneous and other soft tissues	0	2	0	4	2	2	6	4	4	4	6	3	1	6	8	3	5
C50 Breast	2	0	0	0	1	5	15	67	157	246	368	330	349	301	171	112	96
C51 Vulva	0	1	0	0	0	0	0	0	1	3	1	0	5	5	6	3	6
C52 vagina	0	0	0	0	0	0	0	0	0	2	1	3	0	3	7	4	2
C53 Cervix uteri	0	0	0	0	0	0	4	10	38	66	105	133	149	115	95	72	71
C54 Corpus uteri	0	0	0	0	0	0	0	2	6	10	28	39	76	49	35	22	5
C55 Uterus, NOS	0	0	0	1	0	1	0	0	3	12	9	16	25	23	16	9	10
C56 Ovary	0	0	2	1	21	13	18	21	32	58	83	100	95	71	47	46	29
C57 Other and unspecified female genital organs	0	0	0	0	0	0	0	1	0	1	1	5	0	1	1	0	0
C58 Placenta	0	0	0	0	0	2	8	5	3	1	0	0	0	0	0	0	0
C64 Kidney	0	7	1	2	0	0	1	1	2	2	4	3	2	6	6	1	1
C65 Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
C67 Bladder	0	0	0	0	0	1	1	0	2	1	2	5	5	8	8	6	6
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C69 Eye and adnexa	0	8	4	0	0	0	0	2	0	1	3	1	0	1	2	0	0
C70 Meninges	0	0	0	0	0	2	0	0	1	2	0	1	0	0	1	0	0
C71 Brain	1	5	17	6	3	5	3	9	17	14	12	8	18	12	7	3	3
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	1	0	0	0	0	0	0	1	0	2	1	1	0	0	0	0
C73 Thyroid gland	3	0	0	3	16	52	67	120	110	94	84	75	61	44	46	18	22
C74 Adrenal gland	0	6	1	0	0	0	0	1	0	0	2	1	0	0	0	0	0
C75 Other endocrine glands and related structures	0	0	0	2	0	0	0	0	0	0	2	0	0	0	0	0	0
C76 Other and ill-defined sites	0	1	0	0	0	0	0	2	2	1	2	2	1	1	3	0	0
C77 Lymph nodes	0	4	1	4	10	14	11	8	11	10	20	29	23	22	29	27	22
C80 Unknown primary site	4	0	0	0	0	2	3	3	2	15	26	33	41	48	46	41	32
	22	97	52	51	97	126	180	300	462	688	972	1125	1218	1157	898	713	658

Table 10: Cancer cases by ethnicity, sex and sub-site, 2008

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Other		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C00 Lip	43	19	35	11	5	7	3	1	0	0	0	0
C01 Base of tongue	86	16	73	13	11	2	2	1	0	0	0	0
C02 Other and unspecified parts of tongue	312	66	262	45	41	14	6	7	0	0	3	0
C03 Gum	97	43	88	26	8	12	1	5	0	0	0	0
C04 Floor of mouth	89	10	79	5	9	4	1	1	0	0	0	0
C05 Palate	111	32	88	24	23	8	0	0	0	0	0	0
C06 Other and unspecified parts of mouth	443	178	367	105	64	59	9	14	1	0	2	0
C07 Parotid gland	31	37	24	29	2	7	3	1	1	0	1	0
C08 Other and unspecified major salivary glands	15	12	12	7	1	4	2	1	0	0	0	0
C09 Tonsil	111	18	98	15	11	0	2	2	0	0	0	1
C10 Oropharynx	62	7	54	6	7	1	0	0	0	0	1	0
C11 Nasopharynx	28	16	18	8	8	4	2	3	0	0	0	1
C12 Pyriform sinus	167	24	134	19	24	5	9	0	0	0	0	0
C13 Hypopharynx	33	32	30	23	3	8	0	1	0	0	0	0
C14 Other and ill-defined sites in lip, oral cavity and pharynx	48	16	38	11	9	5	0	0	1	0	0	0
C15 Oesophagus	664	617	550	456	97	135	13	22	1	1	3	3
C16 Stomach	239	75	192	60	34	11	12	4	1	0	0	0
C17 Small intestine	25	14	22	11	2	1	1	2	0	0	0	0
C18 Colon	210	238	180	214	17	13	10	10	2	0	1	1
C19 Rectosigmoid junction	22	20	21	16	1	2	0	2	0	0	0	0
C20 Rectum	245	250	203	214	22	17	17	15	1	2	2	2
C21 Anus and anal canal	31	22	27	16	1	4	3	1	0	1	0	0
C22 Liver and intrahepatic bile ducts	129	41	107	37	15	2	7	1	0	0	0	1
C23 Gallbladder	9	29	8	25	1	3	0	1	0	0	0	0
C24 Other and unspecified parts of biliary tract	33	31	24	28	7	2	2	1	0	0	0	0
C25 Pancreas	58	36	48	30	6	5	4	1	0	0	0	0
C26 Other and ill-defined digestive organs	8	8	8	7	0	1	0	0	0	0	0	0
C30 Nasal cavity and middle ear	14	7	11	4	1	2	2	1	0	0	0	0
C31 Accessory sinuses	35	10	30	7	3	3	2	0	0	0	0	0
C32 Larynx	393	48	319	37	56	8	16	3	0	0	2	0
C33 Trachea	1	2	1	2	0	0	0	0	0	0	0	0
C34 Bronchus and lung	813	193	684	167	71	15	52	11	2	0	4	0
C37 Thymus	9	10	8	10	0	0	1	0	0	0	0	0
C38 Heart, mediastinum and pleura	30	8	25	7	1	1	4	0	0	0	0	0
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	1		1		0		0		0		0	
C40 Bones, joints and articular cartilage of limbs	41	24	36	21	4	0	0	3	1	0	0	0

C41	Bones, joints and articular cartilage of other and unspecified sites	26	21	23	18	2	2	1	1	0	0	0	0
C42	Hematopoietic and reticuloendothelial systems	564	502	441	427	71	38	47	36	1	0	4	1
C44	Skin	180	153	152	123	19	21	8	7	1	0	0	2
C47	Peripheral nerves and autonomic nervous system	6	7	5	5	1	1	0	1	0	0	0	0
C48	Retroperitoneum and peritoneum	16	19	15	16	1	0	0	3	0	0	0	0
C49	Connective, subcutaneous and other soft tissues	75	60	67	51	6	5	2	3	0	0	0	1
C50	Breast	63	2220	47	1863	12	196	4	145	0	7	0	9
C51	Vulva		31		24		5		2		0		0
C52	Vagina		22		17		4		1		0		0
C53	Cervix uteri		858		657		147		47		4		3
C54	Corpus uteri		272		236		19		13		4		0
C55	Uterus, NOS		125		101		20		4		0		0
C56	Ovary		637		543	0	62	0	29	0	1	0	2
C57	Other and unspecified female genital organs		10		7		2		1		0		0
C58	Placenta		19		16		2		1		0		0
C60	Penis	74		60		13		0		1		0	
C61	Prostate gland	396		347		29		19		1		0	
C62	Testis	38		32		5		1		0		0	
C63	Other and unspecified male genital organs	4		3		0		1		0		0	
C64	Kidney	107	39	88	29	10	8	9	1	0	0	0	1
C65	Renal pelvis	4	2	4	2	0	0	0	0	0	0	0	0
C66	Ureter	2		2		0		0		0		0	
C67	Bladder	235	45	191	31	22	7	21	7	1	0	0	0
C68	Other and unspecified urinary organs	4	1	3	1	1	0	0	0	0	0	0	0
C69	Eye and adnexa	36	22	33	17	1	0	2	4	0	1	0	0
C70	Meninges	2	7	1	5	1	0	0	2	0	0	0	0
C71	Brain	138	143	109	121	20	8	8	12	0	1	1	1
C72	Spinal cord, cranial nerves and other parts of central nervous system	6	6	5	2	1	3	0	1	0	0	0	0
C73	Thyroid gland	205	815	170	733	12	46	21	33	1	2	1	1
C74	Adrenal gland	5	11	3	10	0	0	2	1	0	0	0	0
C75	Other endocrine glands and related structures	1	4	1	4	0	0	0	0	0	0	0	0
C76	Other and ill-defined sites	33	15	27	13	3	1	2	1	0	0	1	0
C77	Lymph nodes	366	245	295	209	42	24	29	12	0	0	0	0
C80	Unknown primary site	423	296	365	250	44	30	14	11	0	3	0	2
<b>Total</b>		<b>7695</b>	<b>8816</b>	<b>6394</b>	<b>7247</b>	<b>881</b>	<b>1016</b>	<b>377</b>	<b>494</b>	<b>17</b>	<b>27</b>	<b>26</b>	<b>32</b>



**Table 11: Cancer incidence by site and histological type, 2008**

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
<b>Lip, oral cavity &amp; pharynx (C00-C06, C0 9-C14)</b>							
800	Neoplasms, NOS	118	7.2	43	9.0	161	7.6
801-804	Epithelial Neoplasms, NOS	15	0.9	8	1.7	23	1.1
805-808	Squamous cell neoplasms	1471	90.2	399	83.6	1870	88.8
814-838	Adenocarcinomas	11	0.7	12	2.5	23	1.1
843	Mucoepidermoid neoplasms	4	0.2	5	1.0	9	0.4
850-854	Ductal and lobular neoplasms	1	0.1	0	0.0	1	0.0
856-857	Complex epithelial neoplasms	2	0.1	0	0.0	2	0.1
872-879	Malignant nevi and melanomas	0	0.0	1	0.2	1	0.0
893-899	Complex mixed and stromal neoplasms	1	0.1	1	0.2	2	0.1
912-916	Blood vessel tumours	1	0.1	0	0.0	1	0.0
954-957	Nerve sheath tumours	0	0.0	1	0.2	1	0.0
959	Malignant lymphomas, NOS or diffuse	3	0.2	6	1.3	9	0.4
967-969	Mature B-cell lymphomas	3	0.2	0	0.0	3	0.1
973	Plasma cell tumours	0	0.0	1	0.2	1	0.0
<b>Total</b>		<b>1630</b>	<b>100.0</b>	<b>477</b>	<b>100.0</b>	<b>2107</b>	<b>100.0</b>
<b>Parotid, other and unspecified major salivary glands (C07-C08)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	7	15.2	2	4.1	9	9.5
801-804	Epithelial Neoplasms, NOS	6	13.0	0	0.0	6	6.3
805-808	Squamous cell neoplasms	8	17.4	1	2.0	9	9.5
814-838	Adenocarcinomas	8	17.4	20	40.8	28	29.5
843	Mucoepidermoid neoplasms	11	23.9	19	38.8	30	31.6
850-854	Ductal and lobular neoplasms	1	2.2	0	0.0	1	1.1
855	Acinar cell neoplasms	1	2.2	2	4.1	3	3.2
856-857	Complex epithelial neoplasms	0	0.0	1	2.0	1	1.1
880	Soft tissue tumours and sarcomas, NOS	0	0.0	1	2.0	1	1.1
893-899	Complex mixed and stromal neoplasms	3	6.5	3	6.1	6	6.3
967-969	Mature B-cell lymphomas	1	2.2	0	0.0	1	1.1
<b>Total</b>		<b>46</b>	<b>100.0</b>	<b>49</b>	<b>100.0</b>	<b>95</b>	<b>100.0</b>
<b>Digestive organs (C15-C26)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	239	14.3	168	12.2	407	13.3
801-804	Epithelial Neoplasms, NOS	17	1.0	7	0.5	24	0.8
805-808	Squamous cell neoplasms	493	29.5	531	38.5	1024	33.5
812-813	Transitional cell carcinomas	0	0.0	1	0.1	1	0.0
814-838	Adenocarcinomas	815	48.7	610	44.2	1425	46.7
843	Mucoepidermoid neoplasms	0	0.0	1	0.1	1	0.0
844-849	Cystic, mucinous and serous neoplasms	68	4.1	40	2.9	108	3.5
850-854	Ductal and lobular neoplasms	0	0.0	1	0.1	1	0.0
856-857	Complex epithelial neoplasms	2	0.1	1	0.1	3	0.1
872-879	Malignant nevi and melanomas	1	0.1	0	0.0	1	0.0
880	Soft tissue tumours and sarcomas, NOS	2	0.1	1	0.1	3	0.1
889-892	Myomatous neoplasms	4	0.2	1	0.1	5	0.2
893-899	Complex mixed and stromal neoplasms	16	1.0	12	0.9	28	0.9
906-909	Germ cell neoplasms	0	0.0	1	0.1	1	0.0
912-916	Blood vessel tumours	2	0.1	2	0.1	4	0.1
959	Malignant lymphomas, NOS or diffuse	7	0.4	3	0.2	10	0.3
967-969	Mature B-cell lymphomas	7	0.4	1	0.1	8	0.3
<b>Total</b>		<b>1673</b>	<b>100.0</b>	<b>1381</b>	<b>100.0</b>	<b>3054</b>	<b>100.0</b>

<b>Respiratory &amp; intrathoracic organs (C30-C39)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	255	19.7	46	16.5	301	19.1
801-804	Epithelial Neoplasms, NOS	197	15.2	42	15.1	239	15.2
805-808	Squamous cell neoplasms	590	45.5	72	25.9	662	42.1
812-813	Transitional cell carcinomas	2	0.2	0	0.0	2	0.1
814-838	Adenocarcinomas	211	16.3	95	34.2	306	19.4
843	Mucoepidermoid neoplasms	1	0.1	1	0.4	2	0.1
844-849	Cystic, mucinous and serous neoplasms	1	0.1	3	1.1	4	0.3
856-857	Complex epithelial neoplasms	1	0.1	0	0.0	1	0.1
858	Thymic epithelial neoplasms	7	0.5	10	3.6	17	1.1
872-879	Malignant nevi and melanomas	2	0.2	0	0.0	2	0.1
880	Soft tissue tumours and sarcomas, NOS	1	0.1	2	0.7	3	0.2
893-899	Complex mixed and stromal neoplasms	1	0.1	1	0.4	2	0.1
905	Mesothelial neoplasms	3	0.2	1	0.4	4	0.3
906-909	Germ cell neoplasms	10	0.8	0	0.0	10	0.6
912-916	Blood vessel tumours	1	0.1	1	0.4	2	0.1
949-952	Neuroepitheliomatous neoplasms	1	0.1	1	0.4	2	0.1
954-957	Nerve sheath tumours	1	0.1	0	0.0	1	0.1
959	Malignant lymphomas, NOS or diffuse	6	0.5	0	0.0	6	0.4
965-966	Hodgkin lymphoma	1	0.1	0	0.0	1	0.1
967-969	Mature B-cell lymphomas	0	0.0	1	0.4	1	0.1
972	Precursor cell lymphoblastic lymphoma	2	0.2	0	0.0	2	0.1
973	Plasma cell tumours	2	0.2	2	0.7	4	0.3
	<b>Total</b>	<b>1296</b>	<b>100.0</b>	<b>278</b>	<b>100.0</b>	<b>1574</b>	<b>100.0</b>
<b>Bones, joints and articular cartilage (C40- C41)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	2	3.0	0	0.0	2	1.8
912-916	Blood vessel tumours	0	0.0	1	2.2	1	0.9
918-924	Osseous and chondromatous neoplasms	33	49.3	24	53.3	57	50.9
925	Giant cell tumours	4	6.0	1	2.2	5	4.5
926	Miscellaneous bone tumours	18	26.9	15	33.3	33	29.5
927-934	Odontogenic tumours	2	3.0	1	2.2	3	2.7
973	Plasma cell tumours	8	11.9	3	6.7	11	9.8
	<b>Total</b>	<b>67</b>	<b>100.0</b>	<b>45</b>	<b>100.0</b>	<b>112</b>	<b>100.0</b>
<b>Hematopoietic and reticuloendothelial systems (C42)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	0	0.0	3	0.6	3	0.3
814-838	Adenocarcinomas	1	0.2	0	0.0	1	0.1
959	Malignant lymphomas, NOS or diffuse	12	2.1	9	1.8	21	2.0
965-966	Hodgkin lymphoma	2	0.4	1	0.2	3	0.3
967-969	Mature B-cell lymphomas	4	0.7	1	0.2	5	0.5
972	Precursor cell lymphoblastic lymphoma	0	0.0	1	0.2	1	0.1
973	Plasma cell tumours	134	23.8	139	27.7	273	25.6
976	Immunoproliferative diseases	1	0.2	0	0.0	1	0.1
980	Leukemias, NOS	6	1.1	5	1.0	11	1.0
982-983	Lymphoid leukemias	144	25.5	108	21.5	252	23.6
984-993	Myeloid leukemias	196	34.8	177	35.3	373	35.0
994	Other leukemias	4	0.7	5	1.0	9	0.8
995-996	Chronic myeloproliferative disorders	18	3.2	5	1.0	23	2.2
998	Myelodysplastic syndromes	42	7.4	48	9.6	90	8.4
	<b>Total</b>	<b>564</b>	<b>100.0</b>	<b>502</b>	<b>100.0</b>	<b>1066</b>	<b>100.0</b>

<b>Skin (C44)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	3	1.7	2	1.3	5	1.5
801-804	Epithelial Neoplasms, NOS	3	1.7	2	1.3	5	1.5
805-808	Squamous cell neoplasms	105	58.3	56	36.6	161	48.3
809-811	Basal cell neoplasms	20	11.1	40	26.1	60	18.0
814-838	Adenocarcinomas	1	0.6	2	1.3	3	0.9
839-842	Adnexal and skin appendage neoplasms	0	0.0	4	2.6	4	1.2
872-879	Malignant nevi and melanomas	42	23.3	30	19.6	72	21.6
881-883	Fibromatous neoplasms	1	0.6	7	4.6	8	2.4
893-899	Complex mixed and stromal neoplasms	0	0.0	1	0.7	1	0.3
912-916	Blood vessel tumours	0	0.0	1	0.7	1	0.3
959	Malignant lymphomas, NOS or diffuse	0	0.0	1	0.7	1	0.3
970-971	Mature T-cell and NK-cell lymphomas	5	2.8	7	4.6	12	3.6
<b>Total</b>		<b>180</b>	<b>100.0</b>	<b>153</b>	<b>100.0</b>	<b>333</b>	<b>100.0</b>
<b>Peripheral nerves and autonomic nervous system (C47)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
935-937	Miscellaneous tumours	1	16.7	1	14.3	2	15.4
949-952	Neuroepitheliomatous neoplasms	0	0.0	3	42.9	3	23.1
954-957	Nerve sheath tumours	5	83.3	3	42.9	8	61.5
<b>Total</b>		<b>6</b>	<b>100.0</b>	<b>7</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>
<b>Connective, subcutaneous and other soft tissues (C49)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	5	6.8	3	5.6	8	6.3
880	Soft tissue tumours and sarcomas, NOS	30	40.5	21	38.9	51	39.8
881-883	Fibromatous neoplasms	4	5.4	5	9.3	9	7.0
885-888	Lipomatous neoplasms	6	8.1	5	9.3	11	8.6
889-892	Myomatous neoplasms	11	14.9	7	13.0	18	14.1
904	Synovial-like neoplasms	13	17.6	9	16.7	22	17.2
912-916	Blood vessel tumours	4	5.4	2	3.7	6	4.7
918-924	Osseous and chondromatous neoplasms	0	0.0	1	1.9	1	0.8
959	Malignant lymphomas, NOS or diffuse	1	1.4	0	0.0	1	0.8
975	Neoplasms of histiocytes and accessory lymphoid cells	0	0.0	1	1.9	1	0.8
<b>Total</b>		<b>74</b>	<b>100.0</b>	<b>54</b>	<b>100.0</b>	<b>128</b>	<b>100.0</b>
<b>Breast (C50)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	11	17.5	251	11.3	262	11.5
801-804	Epithelial Neoplasms, NOS	0	0.0	7	0.3	7	0.3
805-808	Squamous cell neoplasms	3	4.8	16	0.7	19	0.8
814-838	Adenocarcinomas	2	3.2	23	1.0	25	1.1
844-849	Cystic, mucinous and serous neoplasms	1	1.6	25	1.1	26	1.1
850-854	Ductal and lobular neoplasms	45	71.4	1877	84.5	1922	84.2
856-857	Complex epithelial neoplasms	0	0.0	4	0.2	4	0.2
880	Soft tissue tumours and sarcomas, NOS	1	1.6	2	0.1	3	0.1
881-883	Fibromatous neoplasms	0	0.0	1	0.0	1	0.0
889-892	Myomatous neoplasms	0	0.0	1	0.0	1	0.0
893-899	Complex mixed and stromal neoplasms	0	0.0	1	0.0	1	0.0
900-903	Fibroepithelial neoplasms	0	0.0	10	0.5	10	0.4
959	Malignant lymphomas, NOS or diffuse	0	0.0	2	0.1	2	0.1
<b>Total</b>		<b>63</b>	<b>100.0</b>	<b>2220</b>	<b>100.0</b>	<b>2283</b>	<b>100.0</b>

<b>Female genital organs (C51- C58)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS			242	12.3	242	12.3
801-804	Epithelial Neoplasms, NOS			23	1.2	23	1.2
805-808	Squamous cell neoplasms			750	38.0	750	38.0
812-813	Transitional cell carcinomas			2	0.1	2	0.1
814-838	Adenocarcinomas			506	25.6	506	25.6
844-849	Cystic, mucinous and serous neoplasms			284	14.4	284	14.4
850-854	Ductal and lobular neoplasms			1	0.1	1	0.1
856-857	Complex epithelial neoplasms			4	0.2	4	0.2
859-867	Specialised gonadal neoplasms			18	0.9	18	0.9
872-879	Malignant nevi and melanomas			1	0.1	1	0.1
880	Soft tissue tumours and sarcomas, NOS			5	0.3	5	0.3
881-883	Fibromatous neoplasms			2	0.1	2	0.1
889-892	Myomatous neoplasms			23	1.2	23	1.2
893-899	Complex mixed and stromal neoplasms			35	1.8	35	1.8
900-903	Fibroepithelial neoplasms			3	0.2	3	0.2
905	Mesothelial neoplasms			1	0.1	1	0.1
906-909	Germ cell neoplasms			48	2.4	48	2.4
910	Trophoblastic neoplasms			24	1.2	24	1.2
958	Granular cell tumours and alveolar soft part sarcomas			1	0.1	1	0.1
967-969	Mature B-cell lymphomas			1	0.1	1	0.1
<b>Total</b>				<b>1974</b>	<b>100.0</b>	<b>1974</b>	<b>100.0</b>
<b>Male genital organs (C60 -C63)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	127	24.9			127	24.9
801-804	Epithelial Neoplasms, NOS	4	0.8			4	0.8
805-808	Squamous cell neoplasms	72	14.1			72	14.1
812-813	Transitional cell carcinomas	3	0.6			3	0.6
814-838	Adenocarcinomas	228	44.6			228	44.6
850-854	Ductal and lobular neoplasms	1	0.2			1	0.2
855	Acinar cell neoplasms	38	7.4			38	7.4
859-867	Specialised gonadal neoplasms	1	0.2			1	0.2
880	Soft tissue tumours and sarcomas, NOS	1	0.2			1	0.2
881-883	Fibromatous neoplasms	1	0.2			1	0.2
889-892	Myomatous neoplasms	1	0.2			1	0.2
906-909	Germ cell neoplasms	31	6.1			31	6.1
959	Malignant lymphomas, NOS or diffuse	1	0.2			1	0.2
967-969	Mature B-cell lymphomas	2	0.4			2	0.4
<b>Total</b>		<b>511</b>	<b>100.0</b>			<b>511</b>	<b>100.0</b>
<b>Urinary tract (C64- C68)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	22	6.3	6	6.9	28	6.4
801-804	Epithelial Neoplasms, NOS	4	1.1	0	0.0	4	0.9
805-808	Squamous cell neoplasms	11	3.1	4	4.6	15	3.4
812-813	Transitional cell carcinomas	204	58.0	39	44.8	243	55.4
814-838	Adenocarcinomas	88	25.0	27	31.0	115	26.2
844-849	Cystic, mucinous and serous neoplasms	2	0.6	0	0.0	2	0.5
855	Acinar cell neoplasms	2	0.6	0	0.0	2	0.5
880	Soft tissue tumours and sarcomas, NOS	1	0.3	0	0.0	1	0.2
889-892	Myomatous neoplasms	1	0.3	0	0.0	1	0.2
893-899	Complex mixed and stromal neoplasms	16	4.5	11	12.6	27	6.2
926	Miscellaneous bone tumours	1	0.3	0	0.0	1	0.2
<b>Total</b>		<b>352</b>	<b>100.0</b>	<b>87</b>	<b>100.0</b>	<b>439</b>	<b>100.0</b>

<b>Eye and adnexa (C69)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	2	5.7	0	0.0	2	3.5
801-804	Epithelial Neoplasms, NOS	1	2.9	0	0.0	1	1.8
805-808	Squamous cell neoplasms	8	22.9	3	13.6	11	19.3
814-838	Adenocarcinomas	1	2.9	1	4.5	2	3.5
872-879	Malignant nevi and melanomas	2	5.7	3	13.6	5	8.8
880	Soft tissue tumours and sarcomas, NOS	1	2.9	0	0.0	1	1.8
889-892	Myomatous neoplasms	1	2.9	0	0.0	1	1.8
949-952	Neuroepitheliomatous neoplasms	16	45.7	12	54.5	28	49.1
959	Malignant lymphomas, NOS or diffuse	3	8.6	3	13.6	6	10.5
	<b>Total</b>	<b>35</b>	<b>100.0</b>	<b>22</b>	<b>100.0</b>	<b>57</b>	<b>100.0</b>

<b>Brain and other parts of central nervous system (C70- C72)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	1	0.7	2	1.3	3	1.0
880	Soft tissue tumours and sarcomas, NOS	2	1.4	0	0.0	2	0.7
906-909	Germ cell neoplasms	0	0.0	2	1.3	2	0.7
912-916	Blood vessel tumours	1	0.7	10	6.4	11	3.6
935-937	Miscellaneous tumours	0	0.0	1	0.6	1	0.3
938-948	Gliomas	132	90.4	129	82.7	261	86.4
949-952	Neuroepitheliomatous neoplasms	1	0.7	0	0.0	1	0.3
953	Meningiomas	1	0.7	6	3.8	7	2.3
954-957	Nerve sheath tumours	0	0.0	2	1.3	2	0.7
959	Malignant lymphomas, NOS or diffuse	7	4.8	4	2.6	11	3.6
967-969	Mature B-cell lymphomas	1	0.7	0	0.0	1	0.3
	<b>Total</b>	<b>146</b>	<b>100.0</b>	<b>156</b>	<b>100.0</b>	<b>302</b>	<b>100.0</b>

<b>Thyroid and other endocrine glands (C73- C75)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	12	5.7	22	2.7	34	3.3
801-804	Epithelial Neoplasms, NOS	7	3.3	30	3.6	37	3.6
805-808	Squamous cell neoplasms	0	0.0	5	0.6	5	0.5
812-813	Transitional cell carcinomas	0	0.0	1	0.1	1	0.1
814-838	Adenocarcinomas	178	84.4	738	88.9	916	88.0
844-849	Cystic, mucinous and serous neoplasms	0	0.0	1	0.1	1	0.1
850-854	Ductal and lobular neoplasms	8	3.8	20	2.4	28	2.7
868-871	Malignant paragangliomas and glomus tumours	0	0.0	1	0.1	1	0.1
880	Soft tissue tumours and sarcomas, NOS	0	0.0	1	0.1	1	0.1
906-909	Germ cell neoplasms	1	0.5	1	0.1	2	0.2
935-937	Miscellaneous tumours	0	0.0	1	0.1	1	0.1
949-952	Neuroepitheliomatous neoplasms	4	1.9	7	0.8	11	1.1
959	Malignant lymphomas, NOS or diffuse	1	0.5	0	0.0	1	0.1
967-969	Mature B-cell lymphomas	0	0.0	1	0.1	1	0.1
970-971	Mature T-cell and NK-cell lymphomas	0	0.0	1	0.1	1	0.1
	<b>Total</b>	<b>211</b>	<b>100.0</b>	<b>830</b>	<b>100.0</b>	<b>1041</b>	<b>100.0</b>

<b>Other and ill-defined sites (C76)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	5	15.2	4	26.7	9	18.8
801-804	Epithelial Neoplasms, NOS	5	15.2	1	6.7	6	12.5
805-808	Squamous cell neoplasms	6	18.2	4	26.7	10	20.8
812-813	Transitional cell carcinomas	1	3.0	0	0.0	1	2.1
814-838	Adenocarcinomas	5	15.2	4	26.7	9	18.8
844-849	Cystic, mucinous and serous neoplasms	1	3.0	0	0.0	1	2.1
893-899	Complex mixed and stromal neoplasms	0	0.0	1	6.7	1	2.1
906-909	Germ cell neoplasms	2	6.1	1	6.7	3	6.3
935-937	Miscellaneous tumours	4	12.1	0	0.0	4	8.3
949-952	Neuroepitheliomatous neoplasms	1	3.0	0	0.0	1	2.1
954-957	Nerve sheath tumours	1	3.0	0	0.0	1	2.1
975	Neoplasms of histiocytes and accessory lymphoid cells	2	6.1	0	0.0	2	4.2
	<b>Total</b>	<b>33</b>	<b>100.0</b>	<b>15</b>	<b>100.0</b>	<b>48</b>	<b>100.0</b>

<b>Lymph nodes (C77)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
959	Malignant lymphomas, NOS or diffuse	236	64.5	153	62.4	389	63.7
965-966	Hodgkin lymphoma	59	16.1	47	19.2	106	17.3
967-969	Mature B-cell lymphomas	54	14.8	38	15.5	92	15.1
970-971	Mature T-cell and NK-cell lymphomas	10	2.7	5	2.0	15	2.5
972	Precursor cell lymphoblastic lymphoma	6	1.6	2	0.8	8	1.3
975	Neoplasms of histiocytes and accessory lymphoid cells	1	0.3	0	0.0	1	0.2
	<b>Total</b>	<b>366</b>	<b>100.0</b>	<b>245</b>	<b>100.0</b>	<b>611</b>	<b>100.0</b>

<b>Unknown primary site (C80)</b>		<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>
800	Neoplasms, NOS	170	40.2	128	43.2	298	41.4
801-804	Epithelial Neoplasms, NOS	28	6.6	10	3.4	38	5.3
805-808	Squamous cell neoplasms	102	24.1	31	10.5	133	18.5
812-813	Transitional cell carcinomas	1	0.2	0	0.0	1	0.1
814-838	Adenocarcinomas	120	28.4	116	39.2	236	32.8
844-849	Cystic, mucinous and serous neoplasms	2	0.5	7	2.4	9	1.3
855	Acinar cell neoplasms	0	0.0	1	0.3	1	0.1
872-879	Malignant nevi and melanomas	0	0.0	1	0.3	1	0.1
880	Soft tissue tumours and sarcomas, NOS	0	0.0	1	0.3	1	0.1
906-909	Germ cell neoplasms	0	0.0	1	0.3	1	0.1
	<b>Total</b>	<b>423</b>	<b>100.0</b>	<b>296</b>	<b>100.0</b>	<b>719</b>	<b>100.0</b>

**Table 12: Lip, oral cavity and pharynx  
Incidence data 2008**

Group	Number	Percentage	ASR	Cum. Rate
Male	1630	21.2	18.1	2.23
Female	477	5.4	4.8	0.58
Total	2107	12.8	11.2	1.37

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	0	1	1
C00.1 External lower lip	4	5	9
C00.3 Mucosa of upper lip	0	1	1
C00.4 Mucosa of lower lip	12	3	15
C00.6 Commissure of lip	18	4	22
C00.8 Overlapping lesion of lip	1	0	1
C00.9 Lip, NOS	8	5	13
C01.9 Base of tongue, NOS	86	16	102
C02.0 Dorsal surface of tongue, NOS	4	0	4
C02.1 Border of tongue	8	2	10
C02.2 Ventral surface of tongue, NOS	2	0	2
C02.3 Anterior 2/3 of tongue, NOS	16	4	20
C02.8 Overlapping lesion of tongue	1	1	2
C02.9 Tongue, NOS	281	59	340
C03.0 Upper gum	30	14	44
C03.1 Lower gum	44	22	66
C03.9 Gum, NOS	23	7	30
C04.1 Lateral floor of mouth	1	0	1
C04.9 Floor of mouth, NOS	88	10	98
C05.0 Hard palate	15	10	25
C05.1 Soft palate, NOS	57	11	68
C05.2 Uvula	3	0	3
C05.8 Overlapping lesion of palate	3	1	4
C05.9 Palate, NOS	33	10	43
C06.0 Cheek mucosa	300	135	435
C06.1 Vestibule of mouth	7	0	7
C06.2 Retromolar area	39	10	49
C06.8 Overlapping lesion of other/unspecified parts of mouth	8	6	14
C06.9 Mouth, NOS	89	27	116
C09.0 Tonsillar fossa	2	1	3
C09.8 Overlapping lesion of tonsil	0	1	1
C09.9 Tonsil, NOS	109	16	125
C10.0 Vallecula	41	3	44
C10.4 Branchial cleft	0	1	1
C10.9 Oropharynx, NOS	21	3	24
C11.1 Posterior wall of nasopharynx	0	1	1
C11.3 Anterior wall of nasopharynx	0	2	2
C11.9 Nasopharynx, NOS	28	13	41
C12.9 Pyriform sinus	167	24	191
C13.0 Postcricoid region	27	30	57
C13.1 Aryepiglottic fold	2	2	4
C13.9 Laryngopharynx, Hypopharynx NOS	4	0	4
C14.0 Pharynx, NOS	44	15	59
C14.8 Overlapping lesion of lip, oral cavity, pharynx	4	1	5
Total	1630	477	2107

ICD O code and histology		Male	Female	Total
800	Neoplasms, NOS	118	43	161
801-804	Epithelial Neoplasms, NOS	15	8	23
805-808	Squamous cell neoplasms	1471	399	1870
814-838	Adenocarcinomas	11	12	23
843	Mucoepidermoid neoplasms	4	5	9
850-854	Ductal and lobular neoplasms	1	0	1
856-857	Complex epithelial neoplasms	2	0	2
872-879	Malignant nevi and melanomas	0	1	1
893-899	Complex mixed and stromal neoplasms	1	1	2
912-916	Blood vessel tumours	1	0	1
954-957	Nerve sheath tumours	0	1	1
959	Malignant lymphomas, NOS or diffuse	3	6	9
967-969	Mature B-cell lymphomas	3	0	3
973	Plasma cell tumours	0	1	1
Total		1630	477	2107




Figure 06: Age specific rates- Lip, oral cavity and pharynx



**Table 13: Lip and anterior part of oral cavity  
Incidence data 2008**

Group	Number	Percentage	ASR	Cum. Rate
Male	999	13.0	11.1	1.36
Female	326	3.7	3.3	0.38
Total	1325	8.0	7.0	0.85

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	0	1	1
C00.1 External lower lip	4	5	9
C00.3 Mucosa of upper lip	0	1	1
C00.4 Mucosa of lower lip	12	3	15
C00.6 Commissure of lip	18	4	22
C00.8 Overlapping lesion of lip	1	0	1
C00.9 Lip, NOS	8	5	13
C02.0 Dorsal surface of tongue, NOS	4	0	4
C02.1 Border of tongue	8	2	10
C02.2 Ventral surface of tongue, NOS	2	0	2
C02.3 Anterior 2/3 of tongue, NOS	16	4	20
C02.8 Overlapping lesion of tongue	1	1	2
C02.9 Tongue, NOS	281	59	340
C03.0 Upper gum	30	14	44
C03.1 Lower gum	44	22	66
C03.9 Gum, NOS	23	7	30
C04.1 Lateral floor of mouth	1	0	1
C04.9 Floor of mouth, NOS	88	10	98
C05.0 Hard palate	15	10	25
C06.0 Cheek mucosa	300	135	435
C06.1 Vestibule of mouth	7	0	7
C06.2 Retromolar area	39	10	49
C06.8 Overlapping lesion of other/unspecified parts of mouth	8	6	14
C06.9 Mouth, NOS	89	27	116
Total	999	326	1325

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	78	30	108
805-808 Squamous cell neoplasms	910	279	1189
814-838 Adenocarcinomas	6	9	15
843 Mucoepidermoid neoplasms	2	3	5
850-854 Ductal and lobular neoplasms	1	0	1
856-857 Complex epithelial neoplasms	2	0	2
872-879 Malignant nevi and melanomas	0	1	1
893-899 Complex mixed and stromal neoplasms	0	1	1
912-916 Blood vessel tumours	0	0	0
954-957 Nerve sheath tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
967-969 Mature B-cell lymphomas	0	0	0
973 Plasma cell tumours	0	1	1
Total	999	326	1325

**Table 14: Posterior part of oral cavity and pharynx  
Incidence data 2008**

Group	Number	Percentage	ASR	Cum. Rate
Male	631	8.2	7.0	0.87
Female	151	1.7	1.5	0.20
Total	782	4.7	4.1	0.52

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C01.9 Base of tongue, NOS	86	16	102
C05.1 Soft palate, NOS	57	11	68
C05.2 Uvula	3	0	3
C05.8 Overlapping lesion of palate	3	1	4
C05.9 Palate, NOS	33	10	43
C09.0 Tonsillar fossa	2	1	3
C09.8 Overlapping lesion of tonsil	0	1	1
C09.9 Tonsil, NOS	109	16	125
C10.0 Vallecula	41	3	44
C10.4 Branchial cleft	0	1	1
C10.9 Oropharynx, NOS	21	3	24
C11.1 Posterior wall of nasopharynx	0	1	1
C11.3 Anterior wall of nasopharynx	0	2	2
C11.9 Nasopharynx, NOS	28	13	41
C12.9 Pyriform sinus	167	24	191
C13.0 Postcricoid region	27	30	57
C13.1 Aryepiglottic fold	2	2	4
C13.9 Laryngopharynx, Hypopharynx NOS	4	0	4
C14.0 Pharynx, NOS	44	15	59
C14.8 Overlapping lesion of lip, oral cavity, pharynx	4	1	5
Total	631	151	782

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	55	21	76
805-808 Squamous cell neoplasms	561	120	681
814-838 Adenocarcinomas	5	3	8
843 Mucoepidermoid neoplasms	2	2	4
893-899 Complex mixed and stromal neoplasms	1	0	1
912-916 Blood vessel tumours	1	0	1
959 Malignant lymphomas, NOS or diffuse	3	5	8
967-969 Mature B-cell lymphomas	3	0	3
Total	631	151	782

**Table 15: Trachea, bronchus and lungs  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	814	10.6	9.3	1.23
Female	195	2.2	2.0	0.26
Total	1009	6.1	5.5	0.72

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C33.9 Trachea	1	2	3
C34.0 Main bronchus	17	5	22
C34.1 Upper lobe, lung	29	5	34
C34.2 Middle lobe, lung	4	0	4
C34.3 Lower lobe, lung	8	0	8
C34.9 Lung, NOS	755	183	938
Total	814	195	1009

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	216	42	258
801-804 Epithelial Neoplasms, NOS	187	39	226
805-808 Squamous cell neoplasms	205	25	230
814-838 Adenocarcinomas	200	87	287
843 Mucoepidermoid neoplasms	1	1	2
844-849 Cystic, mucinous and serous neoplasms	1	1	2
893-899 Complex mixed and stromal neoplasms	1	0	1
912-916 Blood vessel tumours	1	0	1
959 Malignant lymphomas, NOS or diffuse	1	0	1
973 Plasma cell tumours	1	0	1
Total	814	195	1009



**Figure 07: Age specific rates- Trachea, bronchus and lungs**

**Table 16: Larynx  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	393	5.1	4.4	0.59
Female	48	0.5	0.5	0.06
Total	441	2.7	2.4	0.31

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C32.0 Glottis	206	14	220
C32.1 Supraglottis	105	25	130
C32.2 Subglottis	1	0	1
C32.3 Laryngeal cartilage	6	3	9
C32.8 Overlapping lesion of larynx	1	0	1
C32.9 Larynx, NOS	74	6	80
Total	393	48	441

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	29	1	30
801-804 Epithelial Neoplasms, NOS	4	1	5
805-808 Squamous cell neoplasms	358	44	402
814-838 Adenocarcinomas	1	0	1
844-849 Cystic, mucinous and serous neoplasms	0	1	1
856-857 Complex epithelial neoplasms	1	0	1
893-899 Complex mixed and stromal neoplasms	0	1	1
Total	393	48	441



**Figure 08: Age specific rates- Larynx**

**Table 17: Oesophagus  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	664	8.6	7.5	0.95
Female	617	7.0	6.4	0.83
Total	1281	7.8	7.0	0.89

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C15.0 Cervical oesophagus	1	1	2
C15.1 Thoracic oesophagus	0	1	1
C15.3 Upper third of oesophagus	22	12	34
C15.4 Middle third of oesophagus	124	158	282
C15.5 Lower third of oesophagus	113	102	215
C15.8 Overlapping lesion of oesophagus	1	0	1
C15.9 Oesophagus, NOS	403	343	746
Total	664	617	1281

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	92	73	165
801-804 Epithelial Neoplasms, NOS	9	5	14
805-808 Squamous cell neoplasms	460	512	972
814-838 Adenocarcinomas	93	23	116
844-849 Cystic, mucinous and serous neoplasms	9	3	12
856-857 Complex epithelial neoplasms	1	1	2
Total	664	617	1281



**Figure 09: Age specific rates- Oesophagus**

**Table 18: Stomach  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	239	3.1	2.7	0.33
Female	75	0.9	0.8	0.11
Total	314	1.9	1.7	0.22

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C16.0 Cardia, NOS	54	15	69
C16.1 Fundus of stomach	3	0	3
C16.3 Gastric antrum	4	2	6
C16.4 Pylorus	3	3	6
C16.5 Lesser curvature of stomach, NOS	0	1	1
C16.8 Overlapping lesion of stomach	0	1	1
C16.9 Stomach, NOS	175	53	228
Total	239	75	314

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	33	13	46
801-804 Epithelial Neoplasms, NOS	2	0	2
805-808 Squamous cell neoplasms	16	5	21
814-838 Adenocarcinomas	155	40	195
844-849 Cystic, mucinous and serous neoplasms	21	14	35
880 Soft tissue tumours and sarcomas, NOS	1	0	1
889-892 Myomatous neoplasms	2	0	2
893-899 Complex mixed and stromal neoplasms	6	3	9
959 Malignant lymphomas, NOS or diffuse	3	0	3
Total	239	75	314



**Figure 10: Age specific rates- Stomach**

**Table 19: Colon and rectum  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	477	6.2	5.3	0.64
Female	508	5.8	5.2	0.64
Total	985	6.0	5.2	0.64

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	22	29	51
C18.1 Appendix	2	1	3
C18.2 Ascending colon	7	4	11
C18.3 Hepatic flexure of colon	2	2	4
C18.4 Transverse colon	7	6	13
C18.5 Splenic flexure of colon	1	2	3
C18.6 Descending colon	3	5	8
C18.7 Sigmoid colon	60	69	129
C18.8 Overlapping lesion of colon	3	1	4
C18.9 Colon, NOS	103	119	222
C19.9 Rectosigmoid junction	22	20	42
C20.9 Rectum, NOS	245	250	495
Total	477	508	985

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	60	47	107
805-808 Squamous cell neoplasms	5	5	10
814-838 Adenocarcinomas	370	428	798
844-849 Cystic, mucinous and serous neoplasms	32	23	55
856-857 Complex epithelial neoplasms	1	0	1
880 Soft tissue tumours and sarcomas, NOS	0	1	1
889-892 Myomatous neoplasms	1	1	2
893-899 Complex mixed and stromal neoplasms	1	0	1
959 Malignant lymphomas, NOS or diffuse	3	3	6
967-969 Mature B-cell lymphomas	4	0	4
Total	477	508	985



**Figure 11: Age specific rates- Colon and rectum**

**Table 20: Colon  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	210	2.7	2.3	0.28
Female	238	2.7	2.4	0.29
Total	448	2.7	2.3	0.29

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	22	29	51
C18.1 Appendix	2	1	3
C18.2 Ascending colon	7	4	11
C18.3 Hepatic flexure of colon	2	2	4
C18.4 Transverse colon	7	6	13
C18.5 Splenic flexure of colon	1	2	3
C18.6 Descending colon	3	5	8
C18.7 Sigmoid colon	60	69	129
C18.8 Overlapping lesion of colon	3	1	4
C18.9 Colon, NOS	103	119	222
Total	210	238	448

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	25	23	48
801-804 Epithelial Neoplasms, NOS	1	1	2
814-838 Adenocarcinomas	159	194	353
844-849 Cystic, mucinous and serous neoplasms	19	16	35
889-892 Myomatous neoplasms	0	1	1
959 Malignant lymphomas, NOS or diffuse	3	3	6
967-969 Mature B-cell lymphomas	3	0	3
Total	210	238	448



**Figure 12: Age specific rates- Colon**



**Table 21: Rectum, anal canal and anus  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	276	3.6	3.1	0.36
Female	272	3.1	2.8	0.35
Total	548	3.3	3.0	0.36

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C20.9 Rectum, NOS	245	250	495
C21.0 Anus, NOS	22	15	37
C21.1 Anal canal	4	4	8
C21.8 Overlapping lesion rectum, anal canal	5	3	8
Total	276	272	548

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	33	23	56
805-808 Squamous cell neoplasms	17	13	30
812-813 Transitional cell carcinomas	0	1	1
814-838 Adenocarcinomas	205	227	432
844-849 Cystic, mucinous and serous neoplasms	15	7	22
856-857 Complex epithelial neoplasms	1	0	1
872-879 Malignant nevi and melanomas	1	0	1
880 Soft tissue tumours and sarcomas, NOS	0	1	1
889-892 Myomatous neoplasms	1	0	1
893-899 Complex mixed and stromal neoplasms	1	0	1
967-969 Mature B-cell lymphomas	2	0	2
Total	276	272	548



**Figure 13: Age specific rates- Rectum, anal canal and anus**

**Table 22: Breast  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	63	0.8	0.7	0.08
Female	2220	25.2	21.8	2.46
Total	2283	13.8	11.6	1.31

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C50.0 Nipple	0	1	1
C50.2 Upper-inner quadrant of breast	0	1	1
C50.9 Breast, NOS	63	2218	2281
Total	63	2220	2283

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	11	258	269
805-808 Squamous cell neoplasms	3	16	19
814-838 Adenocarcinomas	2	23	25
844-849 Cystic, mucinous and serous neoplasms	1	25	26
850-854 Ductal and lobular neoplasms	45	1877	1922
856-857 Complex epithelial neoplasms	0	4	4
880 Soft tissue tumours and sarcomas, NOS	1	2	3
881-883 Fibromatous neoplasms	0	1	1
889-892 Myomatous neoplasms	0	1	1
893-899 Complex mixed and stromal neoplasms	0	1	1
900-903 Fibroepithelial neoplasms	0	10	10
959 Malignant lymphomas, NOS or diffuse	0	2	2
Total	63	2220	2283



**Figure 14: Age specific rates- Breast**

**Table 23: Cervix uteri  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Female	858	9.7	8.6	1.02

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C53.0 Endocervix	2
C53.9 Cervix uteri	856
Total	858

ICD O code and histology	Female
800 Neoplasms, NOS	126
805-808 Squamous cell neoplasms	691
814-838 Adenocarcinomas	38
844-849 Cystic, mucinous and serous neoplasms	2
893-899 Complex mixed and stromal neoplasms	1
Total	858



**Figure 15: Age specific rates- Cervix uteri**

**Table 24: Ovary**  
**Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Female	637	7.2	6.2	0.70

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C56.9 Ovary	637
Total	637

ICD O code and histology	Female
800 Neoplasms, NOS	109
805-808 Squamous cell neoplasms	5
812-813 Transitional cell carcinomas	2
814-838 Adenocarcinomas	166
844-849 Cystic, mucinous and serous neoplasms	273
856-857 Complex epithelial neoplasms	1
859-867 Specialised gonadal neoplasms	18
881-883 Fibromatous neoplasms	1
889-892 Myomatous neoplasms	2
893-899 Complex mixed and stromal neoplasms	7
900-903 Fibroepithelial neoplasms	3
905 Mesothelial neoplasms	1
906-909 Germ cell neoplasms	47
958 Granular cell tumours and alveolar soft part sarcomas	1
967-969 Mature B-cell lymphomas	1
Total	637



**Figure 16: Age specific rates- Ovary**

**Table 25: Skin  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	180	2.3	1.9	0.24
Female	153	1.7	1.5	0.17
Total	333	2.0	1.7	0.20

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C44.0 Skin of lip, NOS	2	5	7
C44.1 Eyelid	1	6	7
C44.2 External ear	5	5	10
C44.3 Skin, other & unspecified parts of face	13	32	45
C44.4 Skin of scalp and neck	15	15	30
C44.5 Skin of trunk	14	16	30
C44.6 Skin of upper limb and shoulder	7	10	17
C44.7 Skin of lower limb and hip	84	47	131
C44.8 Overlapping lesion of skin	1	0	1
C44.9 Skin, NOS	38	17	55
Total	180	153	333

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	6	4	10
805-808 Squamous cell neoplasms	105	56	161
809-811 Basal cell neoplasms	20	40	60
814-838 Adenocarcinomas	1	2	3
839-842 Adnexal and skin appendage neoplasms	0	4	4
872-879 Malignant nevi and melanomas	42	30	72
881-883 Fibromatous neoplasms	1	7	8
893-899 Complex mixed and stromal neoplasms	0	1	1
912-916 Blood vessel tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
970-971 Mature T-cell and NK-cell lymphomas	5	7	12
Total	180	153	333



**Figure 17: Age specific rates- Skin**

**Table 26: Brain  
Incidence data 2008**

Group	Number	Percentage	ASR	Cum. Rate
Male	138	1.8	1.4	0.15
Female	143	1.6	1.4	0.13
Total	281	1.7	1.4	0.14

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C71.0 Cerebrum	2	3	5
C71.1 Frontal lobe	12	8	20
C71.2 Temporal lobe	5	10	15
C71.3 Parietal lobe	26	12	38
C71.4 Occipital lobe	5	5	10
C71.5 Ventricle, NOS	0	2	2
C71.6 Cerebellum, NOS	6	6	12
C71.7 Brain stem	3	17	20
C71.8 Overlapping lesion of brain	14	11	25
C71.9 Brain, NOS	65	69	134
Total	138	143	281

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	0	2	2
880 Soft tissue tumours and sarcomas, NOS	2	0	2
906-909 Germ cell neoplasms	0	2	2
912-916 Blood vessel tumours	1	10	11
938-948 Gliomas	130	126	256
949-952 Neuroepitheliomatous neoplasms	1	0	1
954-957 Nerve sheath tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	4	2	6
Total	138	143	281



**Figure 18: Age specific rates- Brain**

**Table 27: Thyroid gland  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	205	2.7	2.1	0.21
Female	815	9.2	7.4	0.71
Total	1020	6.2	4.8	0.47

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C73.9 Thyroid gland	205	815	1020
Total	205	815	1020

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	19	50	69
805-808 Squamous cell neoplasms	0	5	5
812-813 Transitional cell carcinomas	0	1	1
814-838 Adenocarcinomas	177	736	913
844-849 Cystic, mucinous and serous neoplasms	0	1	1
850-854 Ductal and lobular neoplasms	8	20	28
959 Malignant lymphomas, NOS or diffuse	1	0	1
967-969 Mature B-cell lymphomas	0	1	1
970-971 Mature T-cell and NK-cell lymphomas	0	1	1
Total	205	815	1020



**Figure 19: Age specific rates- Thyroid**

**Table 28: Urinary bladder  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	235	3.5	2.7	0.34
Female	45	0.5	0.5	0.06
Total	280	1.7	1.5	0.19

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C67.5 Bladder neck	0	1	1
C67.7 Urachus	0	1	1
C67.9 Urinary bladder, NOS	235	43	278
Total	235	45	280

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	18	4	22
805-808 Squamous cell neoplasms	7	4	11
812-813 Transitional cell carcinomas	195	36	231
814-838 Adenocarcinomas	11	1	12
844-849 Cystic, mucinous and serous neoplasms	2	0	2
855 Acinar cell neoplasms	2	0	2
Total	235	45	280



**Figure 20: Age specific rates- Urinary bladder**



**Table 29: Hematopoietic and reticuloendothelial system  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	564	7.3	6.2	0.64
Female	502	5.7	5.2	0.52
Total	1066	6.5	5.7	0.57

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C42.0 Blood	1	0	1
C42.1 Bone marrow	561	501	1062
C42.2 Spleen	2	1	3
Total	564	502	1066

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	0	3	3
814-838 Adenocarcinomas	1	0	1
959 Malignant lymphomas, NOS or diffuse	12	9	21
965-966 Hodgkin lymphoma	2	1	3
967-969 Mature B-cell lymphomas	4	1	5
972 Precursor cell lymphoblastic lymphoma	0	1	1
973 Plasma cell tumours	134	139	273
976 Immunoproliferative diseases	1	0	1
980 Leukemias, NOS	6	5	11
982-983 Lymphoid leukemias	144	108	252
984-993 Myeloid leukemias	196	177	373
994 Other leukemias	4	5	9
995-996 Chronic myeloproliferative disorders	18	5	23
998 Myelodysplastic syndromes	42	48	90
Total	564	502	1066



**Figure 21: Age specific rates- Hematopoietic and reticuloendothelial system**

**Table 30: Prostate gland  
Incidence data 2008**


Group	Number	Percentage	ASR	Cum. Rate
Male	396	5.1	4.6	0.58

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C61.9 Prostate gland	396
Total	396

ICD O code and histology	Female
800 Neoplasms, NOS	124
805-808 Squamous cell neoplasms	2
812-813 Transitional cell carcinomas	3
814-838 Adenocarcinomas	227
850-854 Ductal and lobular neoplasms	1
855 Acinar cell neoplasms	38
889-892 Myomatous neoplasms	1
Total	396



**Figure 22: Age specific rates- Prostate gland**

### Staging data of common cancers 2008

Figures 23, 24 and 25 give the staging information of the three main cancers in Sri Lanka. It is important to note that the staging information was available for 845 (37.0%) of breast cancer patients, 402 (46.9%) of cervical cancer patients and 368 (17.5%) of oral cancer patients. The percentages given under different stages are out of the total number of cases with staging information.




Figure 23: Stage at diagnosis- Cervical cancer




Figure 24: Stage at diagnosis- Breast cancer




Figure 25: Stage at diagnosis- Oral cancer

**Table 31: Site & family history of cancer**


Site of cancer	Family History						Total No.
	Present		Absent		Not recorded		
	No.	%	No.	%	No.	%	
Oesophagus (C 15) 1281	11	0.9%	96	7.5%	1174	91.6%	1281
Colon & Rectum (C 18,19, 20)	21	2.1%	48	4.8%	916	93.0%	985
Breast (C 50)2283	77	3.4%	186	8.1%	2020	88.5%	2283
Uterus (C 54,55)	6	1.5%	16	4.0%	375	94.5%	397
Ovary (C 56)	7	1.1%	39	6.1%	591	92.8%	637
Prostate (C 61)	4	1.0%	16	4.0%	376	95.0%	396
Thyroid (C 73.9)	23	2.3%	53	5.2%	944	92.5%	1020
All other sites	100	1.1%	566	6.0%	8846	92.9	9512
<b>Total</b>	<b>249</b>	<b>1.5%</b>	<b>1020</b>	<b>6.2%</b>	<b>15242</b>	<b>92.3%</b>	<b>16511</b>

**Table 32: Site of cancer & bilateral organ involvement**


Site of Cancer (Topography)	Bilateral organ involved		One side organ involved		Total No.
	No.	%	No.	%	
Lung	14	1.4%	970	98.6%	984
Breast	16	0.7%	2267	99.3%	2283
Ovary	157	24.6%	480	75.4%	637

**Table 33: Basis of diagnosis of cancer patients 2008**

Basis of diagnosis	Frequency	Percent
<b>Diagnosed microscopically</b>		
Histology of primary tumour	14,379	87.1
Cytology/ Haematology	665	4.0
Histology of a metastasis	579	3.5
<b>Subtotal</b>	<b>15,623</b>	<b>94.6</b>
<b>Diagnosed non-microscopically</b>		
Clinical only	49	.3
Clinical Investigation including ultrasound, X-ray, endoscopy etc.	399	2.4
Exploratory surgery	14	.1
Laboratory test	20	.1
<b>Subtotal</b>	<b>482</b>	<b>2.9</b>
Unknown/ Not recorded	<b>406</b>	<b>2.5</b>
<b>Total</b>	<b>16,511</b>	<b>100</b>



**Figure 26: Basis of diagnosis**








**Figure 27: Basis of diagnosis by major categories**

**Table 34: Cancer treatment 2008**

<b>Treatment</b>	<b>Frequency</b>	<b>Percentage</b>
Surgery (S)	835	5.1
Radiotherapy (R)	1405	8.5
Chemotherapy (C)	1952	11.8
Hormone (H)	53	0.3
Other -Symptomatic treatment (O)	509	3.1
S + R	935	5.7
S + C	987	6.0
S + H	149	0.9
S + O	176	1.1
R + C	1558	9.4
R + H	49	0.3
R + O	385	2.3
C + H	17	0.1
C + O	552	3.3
H + O	19	0.1
S + R + C	819	5.0
S + R + H	395	2.4
S + R + O	213	1.3
S + C + H	138	0.8
S + C + O	157	1.0
S + H + O	33	0.2
R + C + H	50	0.3
R + C + O	429	2.6
R + H + O	25	0.2
C + H + O	4	0.0
S + R + C + H	460	2.8
S + R + C + O	235	1.4
S + C + H + O	34	0.2
S + R + H + O	84	0.5
R + C + H + O	14	0.1
S + R + C + H + O	123	0.7
Treatment unknown	3717	22.5
<b>Total</b>	<b>16511</b>	<b>100.0</b>

**Figure 28: Percentage of patients who received different types of treatment**





**Table 35: Cancer incidence by geographical area- 2008**

Province	District	Male		Female		Total	
		No.	%	No.	%	No.	%
Central	Not Known	410	5.3	397	4.5	807	4.9
	Kandy	920	12.0	1016	11.5	1936	11.7
	Matale	174	2.3	214	2.4	388	2.3
	Nuwara Eliya	128	1.7	196	2.2	324	2.0
Eastern	Trincomalee	77	1.0	110	1.2	187	1.1
	Bataloa	80	1.0	92	1.0	172	1.0
	Ampara	123	1.6	139	1.6	262	1.6
Northern	Vavuniya	50	0.6	48	0.5	98	0.6
	Mullativu	19	0.2	11	0.1	30	0.2
	Kilinochchi	39	0.5	35	0.4	74	0.4
	Mannar	22	0.3	24	0.3	46	0.3
	Jaffna	177	2.3	208	2.4	385	2.3
North Central	Anuradhapura	252	3.3	262	3.0	514	3.1
	Polonnaruwa	100	1.3	98	1.1	198	1.2
North Western	Kurunegala	471	6.1	597	6.8	1068	6.5
	Puttalam	202	2.6	221	2.5	423	2.6
Sabaragamuwa	Ratnapura	331	4.3	358	4.1	689	4.2
	Kegalle	293	3.8	307	3.5	600	3.6
Southern	Galle	435	5.7	528	6.0	963	5.8
	Matara	274	3.6	332	3.8	606	3.7
	Hambantota	167	2.2	184	2.1	351	2.1
Uva	Moneragala	115	1.5	97	1.1	212	1.3
	Badulla	292	3.8	340	3.9	632	3.8
Western	Colombo	1254	16.3	1517	17.2	2771	16.8
	Gampaha	919	11.9	1087	12.3	2006	12.1
	Kalutara	371	4.8	398	4.5	769	4.7
Total		7695	100.0	8816	100.0	16511	100.0





Figure 29: Cancer Incidence by Districts- 2008




No. Number of cases

CR - Crude Rate per 100,000 population

Cancer Incidence by Districts- 2008




Trachea, Bronchus and Lungs




No. Number of cases

Colon & Rectum




CR - Crude Rate per 100,000 population

Cancer Incidence by Districts- 2008





No. Number of cases



CR - Crude Rate per 100,000 population



Figure 30: Male Cancer Incidence by Districts- 2008



No. Number of cases

CR - Crude Rate per 100,000 population

Male Cancer Incidence by Districts- 2008



No. Number of cases

CR - Crude Rate per 100,000 population

Male Cancer Incidence by Districts- 2008







Figure 31: Female Cancer Incidence by Districts- 2008




No. Number of cases



CR - Crude Rate per 100,000 population

Female Cancer Incidence by Districts- 2008


Oesophagus




Colon & Rectum



Lip, Oral Cavity and Pharynx



Uterus




No. Number of cases

CR - Crude Rate per 100,000 population



Female Cancer Incidence by Districts- 2008



## List of References

- Cancer Registry, National Cancer Control Programme (2013), Cancer Incidence Data, Sri Lanka, 2007
- Cancer Registry, National Cancer Control Programme (2012), Sri Lanka Cancer Incidence Data; Sri Lanka 2006
- Department of Census and Statistics (2012): Number of death by cause, age and sex (2001, 2002, 2003, 2004, 2005, 2006)  
<http://www.statistics.gov.lk/PopHouSat/VitalStatistics/Tables>
- Department of Census and Statistics; Estimated midyear population by age and sex, 2000-2010  
<http://www.statistics.gov.lk/PopHouSat/Mid%20Year%20Population/midyearsex&district.pdf> [01 June 2014]
- Doll, R., Payne, P., Waterhouse, J.A.H. eds (1966). Cancer Incidence in Five Continents, Vol. I. Union Internationale Contre le Cancer, Geneva.
- Fritz, A. Percy, C. Jack, A. Shanmugaratnam, K. Sobin, L. Parkin, D.M. Whelan S. (ed) (2009) International Classification of Diseases of Oncology, 3rd Edition WHO, Geneva
- Glossary of statistical terms; <http://www-dep.iarc.fr/NORDCAN/english/glossary.htm> [01 Dec 2011]
- Indian Cancer Society, Parel, Mumbai, India (2009) Cancer Incidence and Mortality in Greater Mumbai, 2005
- K.S.Chia, A. Seow, H.P. Lee, K. Shanmugaratnam; (2000) Cancer Incidence in Singapore 1993-1997; Singapore Cancer Registry
- Medical Statistics Unit, Ministry of Health, Sri Lanka (2008) Annual Health Statistics, Sri Lanka 2006
- National Cancer Centre, Ministry of Health and Welfare, Republic of Korea (2011) Cancer Facts & Figures 2011
- Segi, M. (1960) Cancer Mortality for Selected Sites in 24 Countries (1950–57). Department of Public Health, Tohoku University of Medicine, Sendai, Japan

## Appendix I- Statistical Terminology

### Population at risk

It is the part of a population which is susceptible to develop a specific cancer. It is defined on the basis of demographic data, such as place of residence, sex, age group, etc. Years of risk duration are counted in person-years

### Incidence

Incidence quantifies the number of new cases of disease that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

### Mortality

It is usually expressed as a rate. It is a measure of the number of deaths (in general due to a specific cause) in a specific population, per unit time. Mortality rate is typically expressed in units of deaths per 1000 individuals per year.

### Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. It is usually expressed as an annual rate per 100,000 persons at risk.

Crude incidence rate

= Total number of cases in the year/ Total midyear population at risk

Crude death rate

= Total number of deaths in the year/ Total midyear population at risk

### Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five-year age categories are used (highest group 75+).

Age –specific incidence rate

= Number of cases in the five-year age group/ population at risk in the corresponding age group

Age –specific death rate

= Number of deaths in the five-year age group/ population at risk in the corresponding age group

### ASR (age-standardised rate)

Standardised rates are statistically constructed summary rates that account for the difference between populations. An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardisation is necessary when comparing several populations that differ with respect to age because age has such a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. In this publication 'World Population' was taken as the standard population.